Krystal Biotech, Inc. (KRYS)

Krystal Biotech, Inc. is trading at $331.60, down 1.23% on the session. The 50 day average sits at $342.10 and the 200 day at $n/a, which puts the stock in a mixed technical position. RSI is at 47.5, which reads as neutral, and MACD is bearish crossover. Volume is below average.

The nearest support is around $327.97 with resistance near $336.28, so that band frames the current range. Average daily movement is roughly $14.38, or about 4.3% of the share price, which is what any stop placement has to allow for. The overall health score of 42 out of 100 combines a trend score of 36, momentum of 40 and a risk score of 56.

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystrophic epidermolysis bullosa; KB801 for neurotrophic keratitis; KB407, which is in Phase 1 clinical trials for treating cystic fibrosis; KB111 for Hailey-Hailey disease; KB707 for solid tumors; KB304 for dynamic wrinkles; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.